J&J MedTech provides medical devices and solutions for various healthcare needs, self-described as part of Johnson & Johnson.

J&J MedTech

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

S Nikhil Kumar

AbbVie Inc.

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Carl Hansen

Kevin Heyries

Véronique Lecault

AbCellera Biologics Inc.

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Metric
Company Name	J&J MedTech	AbbVie Inc.	AbCellera Biologics Inc.	Bayer Aktiengesellschaft
Symbol		ABBV	ABCL	BAYN
MSH ID	COM:JNJMEDICALDEVICES	COM:ABBVIE	COM:ABCELLERA	COM:BAYER
Market	PRIVATE	STOCKS	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare
Industry	Medical Devices	Drug Manufacturers - General	Biotechnology	Drug Manufacturers - General
Country	US	US	CA	DE
Stage
Employee Count		50K	586	98.19K
Website	jnjmedicaldevices.com	abbvie.com	abcellera.com	bayer.com
LinkedIn				bayer
Founders

Metric
Market Cap		296.91B	823.35M	27.44B
Enterprise Value
Monthly Web Traffic	258.88K	1.18M
Web Traffic Growth	-0.06	0.51
Valuation
Raised Capital		15B

Metric
Revenue	54.32B	38.02M	50.32B
Revenue (LTM)
Revenue (NTM)
Gross Profit	45.54B	7.13M	29.46B
EBITDA	18.10B	-192.16M	13.04B
Operating Income	17.43B	-237.21M	8.88B
Net Income	4.86B	-146.40M	-3.11B
EPS	2.75	-0.51	-3.16
Diluted EPS	2.74	-0.51	-3.16
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.72	0.30	0.59
Operating Profit Margin	0.27	-6.15	0.08
EBITDA Margin	0.33	-5.05	0.26
Net Profit Margin	0.11	-3.85	-0.03
Return on Equity	0.57	-0.12	-0.04
Return on Assets	0.04	-0.10	-0.01
Return on Capital Employed	0.15	-0.17	0.04

JNJM

COM:JNJMEDICALDEVICES

J&J MedTech

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	46.58	-11.06	-7.66
P/B Ratio	25.09	1.21	0.84
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.36	35.65	0.63
EV Multiple	17.44	-4.01	-0.89

Metric
Days Sales Outstanding	75.54	546.74
Days Payables Outstanding		4.09K	118.44
Days Inventory Outstanding	102.41	8.82	257.77
Operating Cycle	181.71	747.59	389.93
Cash Conversion Cycle	179.57	589.35	270.05
Asset Turnover	0.40	0.05	0.39

Metric
Operating Cash Flow	22.84B	-43.88M	4.29B
Free Cash Flow	22.06B	-121.38M	1.38B
Cash Flow to Debt	0.38	-0.56	0.16
Operating Cash Flow/Sales	0.42	-1.15	0.16
Free Cash Flow Yield	0.08	-0.05	-0.02

Metric
Cash & Equivalents	12.81B	133.32M	6.24B
Accounts Receivable	66M	-45.93M	727.74M
Inventory	4.10B	1.11M	14.73B
Goodwill	32.29B	47.81M	34.12B
Debt to Capitalization	0.91	0.06	0.57
Debt to Assets	0.45	0.05	0.41
Current Ratio	0.96	8.34	1.13
Quick Ratio	0.83	10.96	0.87

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	1.21
R&D to Revenue	0.14	3.08	0.12
SG&A to Revenue		1.15	0.05